AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy Meeting Abstract

  

Authors:	Scher, H. I.; Graf, R.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Jendrisak, A.; Greene, S.; Rodriguez, A.; Dugan, L.; Fleisher, M.; Lee, J.; Wang, Y.; Landers, M. A.; Dittamore, R. V.
Abstract Title:	AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy
Meeting Title:	52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	34
Issue:	15 Suppl.
Meeting Dates:	2016 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2016-05-20
Start Page:	269s
Language:	English
ACCESSION:	WOS:000404711500109
DOI:	10.1200/JCO.2016.34.15_suppl.5013
PROVIDER:	wos
Notes:	Meeting Abstract: 5013 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/155092